Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 259

Treatment of Venous Thromboembolism in Patients with Active Cancer

Posted by fidest press agency su giovedì, 12 dicembre 2019

The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis® (apixaban) compared to low molecular weight heparin (LMWH) or warfarin for the treatment of venous thromboembolism (VTE) in patients with active cancer (n=14,086). The real-world data analyses were highlighted during oral presentations at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
In a second oral presentation, results from a sub-group analysis of the primary study were highlighted based on different levels of risk for developing recurrent VTE, a blood clot most often found in the legs or lungs. Study findings were generally consistent with the primary analysis. It is important to note that, anticoagulants, including Eliquis, increase the risk of bleeding and can cause serious, potentially fatal bleeding. VTE is the third most common cause of vascular death after heart attack and stroke.i VTE can be a major health problem among patients with cancer, with studies showing that patients with cancer are at a significantly increased risk for VTE compared to those without cancer.ii VTE is also a leading cause of death in cancer patients, and a significant predictor for all-cause mortality.iii,iv
In these real-world analyses, four U.S. commercial insurance claims databases were used to identify VTE patients with active cancer (defined as cancer diagnosis or cancer treatment [chemotherapy, radiation and/or cancer-related surgery] within six months before or 30 days after VTE diagnosis) who initiated apixaban, LMWH, or warfarin within 30 days following the first VTE event. The risk of events was evaluated using a Cox proportional hazard model. Inverse probability treatment weighting (IPTW) was used to balance patient characteristics between apixaban, LMWH, and warfarin cohorts. Patients were followed to the earliest of: health plan disenrollment, death, index therapy discontinuation, switch to another anticoagulant, study end, or a maximum of 6 months. This was done to evaluate the rates of MB, CRNMB, and recurrent VTE (fatal or non-fatal) among VTE patients with active cancer prescribed apixaban, LMWH, or warfarin in routine clinical practice.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: